Evaluating the utility of H-FABP to predict cardiac dysfunction in cancer patients on Anthracycline chemotherapy, Her 2 Targeted therapy and Immunotherapy

This prospective cross-sectional study aims to evaluate the utility of Heart-type Fatty Acid Binding Protein (H-FABP) as an early biomarker for detecting cardiac dysfunction in cancer patients undergoing Anthracycline-based chemotherapy, HER2-targeted therapy, and Immune Checkpoint Inhibitor (ICI) treatment. A total of 100 patients will be enrolled over one year and assessed for cardiac toxicity using H-FABP, Troponin I/T, CK-MB, NT-proBNP, and CRP at baseline, 3 months, and 6 months. Cardiac function will be evaluated using ECG and 2D Echocardiography with Global Longitudinal Strain (GLS). The study will explore the correlation between H-FABP and other biomarkers with GLS changes to determine their predictive value for subclinical cardiotoxicity. Given the high mortality associated with ICI-related myocarditis and the known cardiotoxic potential of anthracyclines and HER2 therapies, early detection is critical. H-FABP, due to its rapid release following myocardial injury, may offer a sensitive tool for early intervention, potentially reducing treatment interruptions and improving patient outcomes. Statistical analysis will involve ANOVA and correlation tests, with significance set at p<0.05. The findings could support integrating H-FABP into routine monitoring protocols, enhancing cardioprotection and allowing safer, uninterrupted cancer therapy delivery.